These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27267359)

  • 1. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 Jun; 353():i3188. PubMed ID: 27267359
    [No Abstract]   [Full Text] [Related]  

  • 2. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 3. Under-representation of frail older people in meta-analysis of dipeptidyl peptidase-4 inhibitors and hypoglycaemia.
    Tufan F; Soyluk O; Bahat G; Karan MA
    BMJ; 2016 Jun; 353():i3183. PubMed ID: 27267463
    [No Abstract]   [Full Text] [Related]  

  • 4. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
    Laakso M; Rosenstock J; Groop PH; Barnett AH; Gallwitz B; Hehnke U; Tamminen I; Patel S; von Eynatten M; Woerle HJ
    Diabetes Care; 2015 Feb; 38(2):e15-7. PubMed ID: 25614693
    [No Abstract]   [Full Text] [Related]  

  • 7. [Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
    Mukai E; Fujimoto S; Inagaki N
    Nihon Rinsho; 2011 May; 69(5):907-11. PubMed ID: 21595280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exorcising the specter of nighttime hypoglycemia.
    Scheiner G
    Diabetes Self Manag; 2012; 29(1):16, 18-20. PubMed ID: 22482132
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of medication adherence in patients with type 2 diabetes mellitus.
    Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
    Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.
    Yamaguchi S; Ikejima M; Furukawa A; Abe M; Nakazaki M; Ishihara H
    Diabetes Res Clin Pract; 2015 Aug; 109(2):e8-e10. PubMed ID: 26025695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
    Currie CJ; Holden SE
    Diabetes Obes Metab; 2014 Oct; 16(10):881-4. PubMed ID: 25040702
    [No Abstract]   [Full Text] [Related]  

  • 17. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas.
    Gallwitz B; Häring HU
    Diabetes Obes Metab; 2010 Jan; 12(1):1-11. PubMed ID: 19788431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authors' reply to Bosco-Lévy and Salvo.
    Romley JA; Gong C; Jena AB; Goldman DP; Williams B; Peters A
    BMJ; 2016 Aug; 354():i4330. PubMed ID: 27496026
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetic nephropathy].
    Araki S
    Nihon Rinsho; 2013 Nov; 71(11):2010-4. PubMed ID: 24397175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.